Search Bar & Filters
Found 185 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effectiveness and safety of elenestinib BLU-263 combined with symptom directed therapy SDT compared to placebo plus SDT in adults with indolent systemic mastocytosis ISM whose symptoms are not well controlled by SDT alone. This Phase 23 randomized, double-blind, placebo-controlled study includes participants from Parts 1 and 2 with ISM, with those in Part 2 continuing into Part 3 for open-label elenestinib treatment. Part K enrolls participants with prior use of selective KIT inhibitors, and additional pharmacokinetic groups will also participate. Participants receive SDT tailored individually and take either oral elenestinib or matching placebo once daily. In Part 1, treatment continues until study completion, while Part 2 involves approximately 48 weeks of dosing. Part 3 and other parts may extend treatment up to about 5 years. The study monitors participants throughout these periods, with dosing and symptom management adjusted as needed. During the study, participants undergo various assessments including symptom scoring with the Indolent Systemic Mastocytosis-Symptom Assessment Form ISM-SAF, safety monitoring for adverse events, and laboratory tests such as serum tryptase levels and KIT D816V allele fraction. Bone marrow mast cells, bone mineral density, and quality of life measures are also evaluated. Researchers track these outcomes at multiple timepoints from baseline up to 5 years to understand treatment impact and participant safety.
Actively Recruiting
Researchers are creating a national registry in Italy to observe and record how multiple myeloma is diagnosed and treated in routine clinical practice. This observational study aims to describe the standard care for patients with multiple myeloma across different hematology centers, reflecting the current situation and variations in treatment and patient characteristics. Both retrospective and prospective data will be collected to provide a comprehensive view. The study involves a non-interventional, multicenter registry that includes patients diagnosed with multiple myeloma since January 1, 2019. Patients are enrolled consecutively during their routine appointments, and data are collected using an electronic platform. Patients participating in other studies may also be included, with baseline and survival data collected during their participation in interventional trials. Hospital visits for data collection occur approximately every six months. Participants will be followed for up to three years, during which researchers will measure overall survival and time to next treatment. Patient-reported outcomes and costs incurred by patients will also be tracked over this period. The study encourages patient involvement and aims to enhance understanding of multiple myeloma care in Italy without altering standard treatment or requiring additional interventions.
Actively Recruiting
Researchers are evaluating new treatment options for metastatic cervical cancer, a condition where cancer has spread from the cervix to other parts of the body. This study focuses on the safety and effectiveness of combining sacituzumab tirumotecan sac-TMT, pembrolizumab, and bevacizumab, compared to standard treatments. The research aims to understand how well these medicines work together and whether they help people live longer or delay cancer progression. The study has two parts. In Part 1, eligible participants receive sac-TMT with pembrolizumab and bevacizumab to assess safety. In Part 2, all participants first undergo standard induction treatment with pembrolizumab, paclitaxel, and cisplatin or carboplatin, with optional bevacizumab. Those whose cancer does not worsen are randomized to receive either pembrolizumab alone or sac-TMT plus pembrolizumab, with optional bevacizumab for maintenance treatment. Treatments are given by intravenous infusion at specified doses and schedules over several months. Participants will be closely monitored throughout the study with regular visits to assess safety, cancer progression, and quality of life. Researchers will track adverse events, treatment tolerability, progression-free survival, and overall survival. Quality of life questionnaires and physical functioning assessments are included to understand the impact of treatment. The study duration may extend up to approximately 69 months for safety follow-up, with various outcome measures evaluated at set intervals.
Actively Recruiting
Researchers are investigating the effects of an experimental drug called BNT323 also known as DB-1303 compared with standard chemotherapy in women with recurrent endometrial cancer that expresses the HER2 protein. This Phase III study includes two groups based on HER2 levels one group with lower HER2 expression 1 or 2 who have previously received immune checkpoint inhibitors, and another with higher HER2 expression 3. The study aims to evaluate how well these treatments control the cancer and their safety profiles. Participants in Cohort 1 will be randomly assigned to receive either BNT323 or a chemotherapy drug chosen by their doctor, such as doxorubicin or paclitaxel or docetaxel if paclitaxel is unsuitable. Cohort 2 participants will receive BNT323 alone. Treatments are given through intravenous infusions and continue until the cancer progresses, unacceptable side effects occur, or consent is withdrawn. The study includes screening, treatment lasting about six months, and long-term follow-up for up to 53 months to monitor survival and other outcomes. During the trial, participants will undergo various assessments including imaging scans to measure tumor size, evaluations of side effects, blood tests to study drug behavior and immune responses, and quality of life questionnaires. Safety follow-up occurs shortly after treatment ends, followed by extended monitoring for treatment effectiveness and survival. Participants are closely observed throughout to understand how well BNT323 works compared to chemotherapy and its impact on health and wellbeing.
Actively Recruiting
Researchers are investigating a combination therapy of BNT326 and pumitamig for adults with advanced or metastatic non-small cell lung cancer NSCLC that has either relapsed, progressed, or is treatment-nafve. The study includes multiple parts to find the best dose levels, assess safety and tolerability, and evaluate how well the therapy works to shrink tumors in this patient population. The trial is open-label and conducted across multiple sites, focusing on participants with confirmed advanced NSCLC where no curative treatment is available. The study consists of three parts Part 1 focuses on finding safe dose combinations of BNT326 with pumitamig Part 2a expands the dose evaluation to examine preliminary effectiveness and safety and Part 2b randomizes participants to optimize dosing and assess the contribution of each therapy component. Participants with prior treatment and those who are treatment-nafve are enrolled in different cohorts. Treatment is administered via intravenous infusion, and dose levels for Part 2b are determined based on earlier results. Participants undergo a screening period before starting treatment, which can continue for up to 24 months or until disease progression or unacceptable side effects occur. Follow-up periods monitor safety, efficacy, and long-term survival, with total involvement expected to last about 36 months unless ongoing benefit warrants extended treatment. Researchers evaluate dose-limiting toxicities, adverse events, tumor response rates, progression-free survival, and pharmacokinetics to understand treatment effects and participant outcomes.
Actively Recruiting
Primary immune thrombocytopenia ITP is a condition where the immune system mistakenly destroys platelets, leading to a low platelet count that increases the risk of bruising and bleeding. This Phase 3 study aims to evaluate the long-term safety, tolerability, and effectiveness of mezagitamab, a subcutaneous injection, in adults with chronic primary ITP. It also studies how the body processes mezagitamab over an extended period. Eligible participants who completed previous mezagitamab studies TAK-079-3002 or TAK-079-1004 may join this continuation trial. Those from TAK-079-1004 must have shown a platelet response previously. Participants receive mezagitamab treatment on demand based on defined dosing criteria and the clinical judgment of the investigator, with treatment courses possibly repeated as needed. During the trial, participants visit the study clinic multiple times for assessments including monitoring treatment-emergent adverse events, platelet response duration, use of rescue therapy, and drug levels in the blood. The study lasts up to about 108 weeks, with evaluations of safety, effectiveness, immunogenicity, and dosing patterns throughout this period.
Actively Recruiting
Researchers are evaluating how well the medicine zasocitinib works and its safety in children and teenagers aged 4 to under 18 with moderate-to-severe plaque psoriasis. The study is conducted in two parts Part A includes both children and teenagers, while Part B includes only children. Initially, only teenagers meeting specific study rules can join, with children joining after sufficient data is available from other studies. In Part A, participants are randomly assigned to receive either zasocitinib or a matching placebo orally once daily for the first 16 weeks. After this, all receive zasocitinib until the study ends. In Part B, all children receive weight-based oral doses of zasocitinib throughout the study. The treatment lasts up to 208 weeks, with a total study participation time of up to 217 weeks, including screening and safety follow-up. Participants will visit the study site multiple times during the study for assessments, including skin evaluations and measuring drug levels in the blood. Researchers will monitor how well participants respond using various psoriasis severity scales and quality of life questionnaires. A safety follow-up period of 4 weeks occurs after treatment ends to monitor any ongoing effects. The study aims to understand zasocitinibs effects and safety in this young population over a long term.
Actively Recruiting
Researchers are evaluating the efficacy and safety of elecoglipron for weight management in adults living with obesity or overweight. This Phase III global study includes two independent, randomized, double-blind, placebo-controlled pivotal studies. Study 1 involves adults without type 2 diabetes mellitus T2DM, while Study 2 includes adults with T2DM. Participants have obesity or overweight with at least one weight-related comorbidity such as hypertension, prediabetes, dyslipidemia, cardiovascular disease, or obstructive sleep apnea. Participants will be randomly assigned to receive one of two doses of elecoglipron or a placebo once daily as oral tablets. The treatment lasts 72 weeks, and the study is conducted in multiple centers worldwide. The primary measure is the percentage change in body weight from baseline at 72 weeks. Secondary measures include absolute weight loss, achievement of specific weight loss percentages, waist circumference reduction, glycemic control, and systolic blood pressure reduction. Throughout the study, participants will undergo regular assessments including body weight and waist measurements, laboratory tests related to glycemic control, and blood pressure monitoring. Researchers will also track the achievement of normoglycemia and glycemic control in participants with elevated HbA1c levels. Safety and efficacy data will be collected until the study completion in 2029, with participants monitored closely during the 72-week treatment period.
Actively Recruiting
Healthy Volunteer
Neurodegenerative diseases NDGs such as Amyotrophic Lateral Sclerosis, Alzheimers Disease, and Parkinsons Disease are common and serious disorders affecting older adults. This research investigates the muscle-brain connection, particularly the neuromuscular junction NMJ, to understand its role in aging and these neurological disorders. The study explores whether changes in NMJ and muscle function could signal early disease signs or influence disease progression. The study observes two groups one with neurodegenerative diseases and another representing good aging without muscular or neurological impairments. It collects clinical and biological data, including muscle and neurological assessments and biological markers like miRNA and extracellular vesicles. These data will help identify factors influencing the muscle-brain relationship and movement issues. Participants will undergo evaluations including the Edmonton Frail Scale at baseline and after six months. The study gathers information on muscle and brain function, movement, and biomarkers to track changes over time. This observational study aims to identify risk factors and disease patterns to support future strategies for minimizing risks associated with aging and neurological conditions.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of chemotherapy treatments in adults diagnosed with Blastic Plasmacytoid Dendritic Cell Neoplasm BPDCN. This observational study aims to provide comparative data to the ELZONRIS registry study by reviewing real-world outcomes of patients treated with various chemotherapy regimens as their first-line therapy since May 2016. Participants have received chemotherapy regimens similar to those used for acute myeloid leukemia, acute lymphocytic leukemia, or lymphoma, with choices made by their healthcare providers based on institutional practices. No study medication is provided by the sponsor. The study collects data retrospectively without administering new treatments. During the study, researchers collect information on response rates, duration of response, progression-free and overall survival, adverse events, transfusion needs, treatment durations, hospitalization details, and transitions to stem cell transplant. Data is gathered from the start of treatment through up to 26 months, offering insights into treatment patterns and outcomes. Participants privacy and consent are managed following local regulations.
1-10 of 185
1